Protein Biomarkers And Risk Scores In Pulmonary Arterial Hypertension Associated With Ventricular Septal Defect: Integration Of Multi-Omics And Validation
Chao Yuan,Huan-Xin Chen,Hai-Tao Hou,Jun Wang,Qin Yang,Guo-Wei He
DOI: https://doi.org/10.1152/ajplung.00167.2020
2020-01-01
Abstract:The molecular mechanisms underlying pulmonary arterial hypertension (PAH) in congenital ventricular septal defects (VSD) are unclear. We aimed to reveal molecular pathways and potential biomarkers by multi-omics analysis in VSD-PAH. Plasma from 160 children, including 120 VSD patients with/without PAH and 40 healthy children was studied by integrated proteomics, metabolomics, and bioinformatics analyses. Proteomics identified 107 differential proteins (DPs)-between patients with/without PAII including significantly increased adiponectin (ADIPO), dopamine beta-hydroxylase (DBH), alanyl membrane aminopeptidase (ANPEP), transferrin receptor 1, and glycoprotein Ib platelet alpha-subunit and decreased guanine nucleotide-binding protein Gs in VSD-PAH. Metabolomics discovered 191 differential metabolites between patients with/without PAH. including elevation of serotonin, taurine, creatine, sarcosine. and 2-oxobutanoate, and decrease of vanillylmandelic acid. 3,4-dihydroxymandelate, 15-keto-prostaglandin F-2 alpha, fructose 6-phosphate, L-glutamine, dehydroascorbate, hydroxypyruvate, threonine, L-cystine. and 1-aminocyclopropane-l-carboxylate. The DPs-were validated in a new cohort of patients (n = 80). Integrated analyses identified key pathways, including cAMP, ECM receptor interaction, AMPK, hypoxia-inducible factor 1, PI3K-Akt signaling pathways, and amino acid metabolisms. Increased plasma protein levels of DBH, ADIPO, and ANPEP were found to be independently associated with the occurrence of PAH. with a new total risk score from these three proteins developed for clinical diagnosis. In this integrated multi-omics analysis in VSD-PAH patients, we have, for the first time, found that VSD-PAH patients present important differential proteins, metabolites, and key pathways. We have developed a total risk score (based on the plasma concentration of DBH, ANPEP, and ADIPO) as a predictor of development of PAH in CHD-VSD patients. Therefore, these proteins may be used as biomarkers, and the new total risk score has significant clinical implications in the diagnosis of PAH.